On Watch list for 2019.
Possible Hidden Gem.
Even for the empty shall at these levels stock looks attractive.
AS - 950 M
OS - 62.5 M
Debt - 29k !!!
If they drop Kasten name for "DAKOTA Life Sciences" - will be big!
Company Products Timeline
• 2011 – 2016: Founded with focus on innovative drug products to overcome global
drug resistance and meet urgent drug crises in the United States. National awards
and Woundcare Community peer reviews for proprietary technology that revives
original efficacy of legacy drugs through improved site-specific drug delivery.*
• 2017: Acquired exclusive global development and commercialization rights to
Lotilibcin prescription antibiotic. IND already open at US FDA. Robust pipeline of drug
products with no drug resistance profile.
• 2018: U.S. drug clinical trials and Block Chain Security/Safety/Surveillance (BCS3)
software system development. BCS3 for global drug use tracking and for integration of
proprietary genomics-based global drug efficacy surveillance networks. Extends
reliability and useful life of medications with added safety for patients.
• 2019: Prescription drug allowance(s) and deployment of BCS3.
Experienced Senior Development &
Commercial Leadership
Steven Keough – President & Chief Executive Officer
SVP SurModics (NASDAQ:SRDX); public and private drug delivery company management; life sciences patent counsel two decades and International Edison Awards Judge. U.S. Naval Academy, Annapolis, BS, Catholic University of America, MA, Boston College Law School, JD, and
executive studies at University of Chicago, Graduate School of Business.
Dhan Mhasker, PhD – Chief Scientific Officer & Director of Manufacturing
Drug Delivery Manufacturing Leadership: Private Label Partners; Prism Research; Omega Biotech; University of Pune, India, PhD, Post-Doc University Positions at University of Southern California and The Ohio State University.
Dr. David Armstrong, DPM, MD, PhD – Chair, Wound Repair Advisory Team
Professor of Surgery (tenured) University of Arizona; Co-Founder, Southern Arizona Limb Salvage Alliance and Deputy Director of the Arizona
Center for Accelerated Biomedical Innovation; Fellow, Royal College of Surgeons (Glasgow), Member, Podiatric Medicine Hall of Fame. Dr.
Armstrong was the first podiatric surgeon to become a member of the Society of Vascular Surgery. University of Manchester College of Medicine,
PhD, University of Wales College of Medicine, MS in Tissue Repair & Wound Healing.
Robert Britting, MBA – Vice President, RX Commercialization
Chief Healthcare Strategist, BI Worldwide Ltd, VP Healthcare Divisions, Saatchi & Saatchi Worldwide and Foote Cohn Belding; Knoll Pharma, President/CEO Health Initiatives, Founder: African Institute for Medical Education, Fairleigh Dickenson University, MBA.
Kevin Lacey, MBA – Controller
Wyndom (NASDAQ:WYN) and Starwood (NASDAQ:HOT) financial and marketing leadership Positions, Controller at Iron Solutions, Director of Accounting SouthComm Communications, Senior CPA at 13
Management LLC (Taylor Swift artist management), multiple contract CFO positions as private practice CPA,
University of Central Florida, MBA, Webber College, BS and Accounting.
Core Science Advisors
Jerome J. Schentag, Pharm D – Pharmaceuticals, pharmacology, infectious disease, microbiota
Philadelphia College of Pharmacy, Pharm D; University of Nebraska, BSc, Pharmacy; Professor of Pharmaceutics & Pharmacy (ret) State University of New York in Buffalo; Fellow in the American College of Clinical Pharmacy; Fellow, Center for Entrepreneurial Leadership, SUNY at
Buffalo School of Management; Served on the editorial boards of the journals Pharmacotherapy, Annals of Pharmacotherapy, Antimicrobial Agents
and Chemotherapy, Pharmaceutical Research, and Clinical Pharmacology and Therapeutics. 30+ years of US and Global Clinical Trial expertise in
Infectious Diseases, Critical Care, Sepsis and Metabolic Syndrome; CEO and President, TheraSyn Sensors.
Hirofumi Nakajima, PhD – Pharmaceutical R&D
University of Hokkaido Graduate School of Medicine, PhD; Specialty area of infectious diseases based on his scientific background in
pharmacy, biochemistry, microbiology and bacteriology. 12+ years R&D with Lotilicin drug, including developer of Lotilibcin IV and principal inventor of global patent portfolio for Lotilibcin IV formulation; R&D scientist at AriGen (Japan) and Kyoto BioPharma (Japan). Inventor on Lotilibcin topical patent
applications currently assigned to Company, and Chief Scientist for pre-clinical work on Lotilibcin topical projects.
Yossef Av-Gay, PhD – Microbiology & Tuberculosis
Tel Aviv University, Microbial Genetics, PhD; Tel Aviv University, Microbiology, MSc; Tel Aviv University, Biology, BSc; Professor, Division of
Infectious Diseases, University of British Colombia; Associate Member, Department of Microbiology and Immunology UBC, & Division of Respiratory
Medicine, UBC-VGH; Breakthroughs in molecular genetics and biochemistry of mycobacterium; editor for the Journal of Biological Chemistry, member
of the scientific review panels of the Canadian Institute of Health Research, the French Agence Nationale de la Recherche, Innovative Medicine
Innovations, The UK Welcome Trust, US National Institute of Health, and the European Commission FP6 and FP7 programs; Founder, Enox
Biopharma Inc. & AIT Ltd.
Gilead Kedem, MD – Bioinformatics & Software
Sackler School of Medicine, MD, Tel Aviv, Israel; Graduate Studies in Biomedical Engineering, The Johns Hopkins University; University of Maryland (BS, Physics). Genome Therapeutics Corp, Anvil, Inc., Genetics
Institute, Millenium Pharmaceuticals, Sanofi-Aventis Cambridge Genomics Center.
Made in USA! Research, Development,
Manufacturing! Accessible.
PRIMARY FACILITIES IN CONNECTICUT,SOUTH DAKOTA AND CALIFORNIA.
Time will tell.
On Watch list.
